SG10201401054YA - Peptides and compositions for prevention of cell adhesion and methods of using same - Google Patents

Peptides and compositions for prevention of cell adhesion and methods of using same

Info

Publication number
SG10201401054YA
SG10201401054YA SG10201401054YA SG10201401054YA SG10201401054YA SG 10201401054Y A SG10201401054Y A SG 10201401054YA SG 10201401054Y A SG10201401054Y A SG 10201401054YA SG 10201401054Y A SG10201401054Y A SG 10201401054YA SG 10201401054Y A SG10201401054Y A SG 10201401054YA
Authority
SG
Singapore
Prior art keywords
peptides
prevention
compositions
methods
same
Prior art date
Application number
SG10201401054YA
Inventor
Amir Zlotkin
Original Assignee
Tel Hashomer Medical Res Infrastructure & Services Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tel Hashomer Medical Res Infrastructure & Services Ltd filed Critical Tel Hashomer Medical Res Infrastructure & Services Ltd
Publication of SG10201401054YA publication Critical patent/SG10201401054YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F1/00—Treatment of water, waste water, or sewage
    • C02F1/44—Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis
    • C02F1/441—Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis by reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F1/00—Treatment of water, waste water, or sewage
    • C02F1/50—Treatment of water, waste water, or sewage by addition or application of a germicide or by oligodynamic treatment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F2303/00—Specific treatment goals
    • C02F2303/04—Disinfection
    • C—CHEMISTRY; METALLURGY
    • C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F2303/00—Specific treatment goals
    • C02F2303/20—Prevention of biofouling
SG10201401054YA 2008-12-29 2009-12-28 Peptides and compositions for prevention of cell adhesion and methods of using same SG10201401054YA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19382108P 2008-12-29 2008-12-29

Publications (1)

Publication Number Publication Date
SG10201401054YA true SG10201401054YA (en) 2014-07-30

Family

ID=42115606

Family Applications (3)

Application Number Title Priority Date Filing Date
SG2011044674A SG172244A1 (en) 2008-12-29 2009-12-28 Peptides and compositions for prevention of cell adhesion and methods of using same
SG10201504379VA SG10201504379VA (en) 2008-12-29 2009-12-28 Peptides and compositions for prevention of cell adhesion and methods of using same
SG10201401054YA SG10201401054YA (en) 2008-12-29 2009-12-28 Peptides and compositions for prevention of cell adhesion and methods of using same

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG2011044674A SG172244A1 (en) 2008-12-29 2009-12-28 Peptides and compositions for prevention of cell adhesion and methods of using same
SG10201504379VA SG10201504379VA (en) 2008-12-29 2009-12-28 Peptides and compositions for prevention of cell adhesion and methods of using same

Country Status (13)

Country Link
US (5) US8552147B2 (en)
EP (1) EP2376528B1 (en)
JP (2) JP5758302B2 (en)
KR (1) KR101383408B1 (en)
CN (1) CN102272147B (en)
AU (1) AU2009334452B2 (en)
CA (2) CA2748121C (en)
DK (1) DK2376528T3 (en)
ES (1) ES2528133T3 (en)
HK (1) HK1161607A1 (en)
IL (1) IL213748A (en)
SG (3) SG172244A1 (en)
WO (1) WO2010076642A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8669418B2 (en) 2005-12-22 2014-03-11 Vib Vzw Means and methods for mediating protein interference
BRPI0811530B1 (en) 2007-05-14 2019-01-02 Research Foundation Of State Univ Of New York composition comprising inducer (s) of physiological response to decanoic acid dispersion, surface, solution, ex vivo method of treating or inhibiting the formation of a biofilm on a surface
SG10201504623VA (en) 2008-09-24 2015-07-30 Tel Hashomer Medical Res Infrastructure & Services Ltd Peptides and compositions for prevention of cell adhesion and methods of using same
SG172244A1 (en) 2008-12-29 2011-07-28 Tel Hashomer Medical Res Infrastructure & Services Ltd Peptides and compositions for prevention of cell adhesion and methods of using same
US11174299B2 (en) * 2008-12-29 2021-11-16 Dispersebio Ltd. Peptides and compositions for prevention of cell adhesion and methods of using same
LT2683419T (en) * 2011-03-11 2018-07-25 Vib Vzw Molecules and methods for inhibition and detection of proteins
CN104039812A (en) * 2011-05-31 2014-09-10 和黄生物膜医疗解决方案有限公司 Dispersion and detachment of cell aggregates
CN105828828A (en) * 2013-10-31 2016-08-03 和黄生物膜医疗解决方案有限公司 Prevention and dispersion of biolfilm
US10733199B2 (en) * 2014-11-05 2020-08-04 International Business Machines Corporation Optimizing data conversion using pattern frequency
CA3058848A1 (en) 2017-05-09 2018-11-15 Vib Vzw Means and methods for treating bacterial infections
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
EP3699185A1 (en) * 2019-02-20 2020-08-26 Université de Rennes 1 Peptides for preventing biofilm formation

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (en) 1971-02-10 1977-09-15 Organon Nv METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES.
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
NL154599B (en) 1970-12-28 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES, AND TEST PACKAGING.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (en) 1972-05-11 1983-06-01 Akzo Nv METHOD FOR DETERMINING AND DETERMINING BITES AND TEST PACKAGING.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4286988A (en) 1980-06-30 1981-09-01 The United States Of America As Represented By The Secretary Of The Navy Copper base antifouling paints with pH control
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4678512A (en) 1982-02-12 1987-07-07 Grams Ralph R Marine coating compositions and method
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
GB8511144D0 (en) 1985-05-02 1985-06-12 Int Paint Plc Marine anti-fouling paint
US4865909A (en) 1987-10-21 1989-09-12 W. L. Gore & Associates, Inc. Microporous anti-fouling marine coating
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5143545A (en) 1991-09-20 1992-09-01 The United States Of America As Represented By The Secretary Of The Navy Antifouling marine coatings
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
HU219815B (en) 1995-02-07 2001-08-28 Fidia Advanced Biopolymers S.R.L. Process for the coating of objects with hyaluronic acid, derivatives thereof, and semisynthetic polymers
WO2002068638A1 (en) * 2001-02-23 2002-09-06 Human Genome Sciences, Inc. 83 human secreted proteins
US20020146692A1 (en) * 2000-01-21 2002-10-10 Victoria Yamazaki Methods and materials relating to G protein-coupled receptor-like polypeptides and polynucleotides
US20020143149A1 (en) * 2000-09-13 2002-10-03 Duckworth David M. Seven trans-membrane receptor-Fitz2
WO2002061087A2 (en) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
WO2003006048A1 (en) * 2001-07-11 2003-01-23 Jari Pharmaceuticals B.V. Combination of chips (chemotaxis inhibiting protein from staphylococcus aureus)-based compounds
US7189351B2 (en) 2001-10-25 2007-03-13 Spherix Incorporated D-tagatose as an anti-biofilm agent
CA2569511A1 (en) * 2004-06-14 2005-12-22 Galapagos N.V. Methods for identification, and compounds useful for the treatment of degenerative & inflammatory diseases
WO2006006172A2 (en) 2004-07-15 2006-01-19 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
US20070293435A1 (en) 2006-06-16 2007-12-20 Naomi Balaban Identification and Use of Non-Peptide Analogs of RNAIII-Inhibiting Peptide for the Treatment of Staphylococcal Infections
KR20140068239A (en) 2007-09-20 2014-06-05 텔 하쇼머 메디컬 리서치 인프라스트럭쳐 앤드 서비시스 리미티드． Compositions of aquatic origin for prevention of cell adhesion and methods of using same
SG10201504623VA (en) * 2008-09-24 2015-07-30 Tel Hashomer Medical Res Infrastructure & Services Ltd Peptides and compositions for prevention of cell adhesion and methods of using same
SG172244A1 (en) 2008-12-29 2011-07-28 Tel Hashomer Medical Res Infrastructure & Services Ltd Peptides and compositions for prevention of cell adhesion and methods of using same
WO2010078842A1 (en) 2009-01-07 2010-07-15 Huang Haidong Gene encoding human glucokinase mutant, enzyme encoded by the same, recombinant vectors and hosts, pharmaceutical compositions and uses thereof, methods for treating and preventing diseases
CN104039812A (en) 2011-05-31 2014-09-10 和黄生物膜医疗解决方案有限公司 Dispersion and detachment of cell aggregates

Also Published As

Publication number Publication date
IL213748A0 (en) 2011-07-31
CA2967412C (en) 2018-07-17
CN102272147A (en) 2011-12-07
US20120015870A1 (en) 2012-01-19
JP2012513979A (en) 2012-06-21
CA2748121C (en) 2017-12-12
AU2009334452B2 (en) 2015-06-11
JP2015107975A (en) 2015-06-11
KR101383408B1 (en) 2014-04-17
US8552147B2 (en) 2013-10-08
US20150259390A1 (en) 2015-09-17
SG10201504379VA (en) 2015-07-30
DK2376528T3 (en) 2015-01-05
EP2376528A1 (en) 2011-10-19
HK1161607A1 (en) 2012-07-27
AU2009334452A1 (en) 2011-07-21
WO2010076642A1 (en) 2010-07-08
JP5758302B2 (en) 2015-08-05
US9732124B2 (en) 2017-08-15
US20200062808A1 (en) 2020-02-27
CA2967412A1 (en) 2010-07-08
US20140155318A1 (en) 2014-06-05
CN102272147B (en) 2017-09-12
CA2748121A1 (en) 2010-07-08
ES2528133T3 (en) 2015-02-04
KR20110119646A (en) 2011-11-02
US9045550B2 (en) 2015-06-02
EP2376528B1 (en) 2014-11-26
US11566054B2 (en) 2023-01-31
JP6203168B2 (en) 2017-09-27
IL213748A (en) 2017-10-31
SG172244A1 (en) 2011-07-28
US20180186845A1 (en) 2018-07-05
US10508136B2 (en) 2019-12-17

Similar Documents

Publication Publication Date Title
HK1213903A1 (en) Peptides and compositions for prevention of cell adhesion and methods of using same
HK1161607A1 (en) Peptides and compositions for prevention of cell adhesion and methods of using same
IL217389A0 (en) Methods and compositions for the recombinant biosynthesis of n-alkanes
IL209136A0 (en) Compositions of peptides and processes of preparation thereof
EP2373679A4 (en) Mini-hepcidin peptides and methods of using thereof
EP2334185A4 (en) Compositions and methods of using (r)-pramipexole
HK1144823A1 (en) Compositions and methods of using proislet peptides and analogs thereof
GB201006373D0 (en) Sealing compositions and methods
EP2334804A4 (en) Co-culture compositions and methods
IL224959A (en) Methods and compositions for generation of bax-deficient cell line
EP2442829A4 (en) Structured viral peptide compositions and methods of use
HK1153360A1 (en) Sweetener compositions and methods of making them
HK1144319A1 (en) Compositions and methods of detecting tiabs
SG10201701670SA (en) Compositions of aquatic origin for prevention of cell adhesion and methods of using same
EP2356462A4 (en) Anti-cxcr1 compositions and methods
IL208445A0 (en) Compositions and methods for immunotherapy
PL2274002T3 (en) Leucine-rich peptide compositions and methods for isolation
HK1140019A1 (en) Compositions and methods of detection
EP2346521A4 (en) Peptides and methods of use
IL207827A0 (en) Apoaequorin-containing compositions and methods of using same
HK1151242A1 (en) Mntf peptide compositions and methods of use mntf
IL204645A0 (en) Compositions of aquatic origin for prevention of cell adhesion and methods of using same
PL385727A1 (en) Composition intended for sealing plates and method of preparation of the composition for the sealing plates
GB0820492D0 (en) Cell compositions and uses thereof
GB0803464D0 (en) Methods and compositions